PixelServer

Gene mutation lets leukemia fight drug that helps remission

May 2, 2007

Researchers at the BC Cancer Agency’s Terry Fox Laboratory discovered that chronic myeloid leukemia (CML) stem cells spontaneously develop resistance to Gleevec, possibly due to continuing genetic mutations. Gleevec is an oral chemotherapy drug that helps reduce the symptoms of CML and allows patients to return to a normal life.